McCall McPherson explains how inflammation drives chronic disease and why GLP-1 therapies reduce it. He cites patient outcomes from his program and his own experience as evidence that these drugs significantly lower inflammation, especially in people with autoimmune thyroid conditions.
Chapters
So let's talk about the number one most common benefit that we see with patients in our program. Inflammation reduction. So inflammation is the core driver of chronic disease. It is what breaks our physiology, our body down over time and yields us less and less healthy as the years go. Obviously, people with thyroid issues, especially those with autoimmune thyroid conditions, clearly have inflammatory issues. But I think, honestly, the general population of the world, but most especially America, we have inflammation issues, myself included. I struggle with inflammation. If you guys follow me, you know that I'm always constantly working on my inflammatory level. I have never, ever seen anything that holds a candle to the inflammatory reduction of a GLP1.